4.7 Article

Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis

Journal

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 306, Issue 16, Pages 1765-1774

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2011.1529

Keywords

-

Funding

  1. la Federation Francaise de Cardiologie
  2. Abbott Vascular
  3. AstraZeneca
  4. CLS Behring
  5. Daiichi Sankyo
  6. Eli Lilly
  7. Biotronik
  8. Iroko Cardio
  9. Fondation de France
  10. INSERM
  11. Federation Francaise de Cardiologie
  12. Medco Research Institute
  13. Medco Health Solutions
  14. sanofi-aventis
  15. Brahms
  16. Societe Francaise de Cardiologie
  17. Servier
  18. Boston Scientific
  19. Cordis
  20. Guerbet Medical
  21. ITC Edison
  22. Medtronic
  23. Pfizer
  24. Stago
  25. Bayer
  26. Cardiovascular Research Foundation
  27. Cleveland Clinic Research Foundation
  28. Duke Institute
  29. Europa
  30. Lead-up
  31. GlaxoSmithKline
  32. Institut de Cardiologie de Montreal
  33. Menarini
  34. Nanospheres
  35. Novartis
  36. Portola
  37. Medicines Company
  38. TIMI Study Group
  39. Bristol-Myers Squibb
  40. ACTION
  41. SGAM Foundation

Ask authors/readers for more resources

Context Despite dual antiplatelet therapy, stent thrombosis remains a devastating and unpredictable complication of percutaneous coronary intervention (PCI). Objective To perform a sequential analysis of clinical and genetic factors associated with definite early stent thrombosis. Design, Setting, and Participants Case-control study conducted in 10 centers in France between January 2007 and May 2010 among 123 patients undergoing PCI who had definite early stent thrombosis and DNA samples available, matched on age and sex with 246 stent thrombosis-free controls. Main Outcome Measure Accuracy of early stent thrombosis prediction by 23 genetic variants. Results Among the 23 genetic variants investigated in 15 different genes, the significant determinants of early stent thrombosis were CYP2C19 metabolic status (adjusted odds ratio [OR], 1.99; 95% CI, 1.47-2.69), ABCB1 3435 TT genotype (adjusted OR, 2.16; 95% CI, 1.21-3.88), and ITGB3 PLA2 carriage (adjusted OR, 0.52; 95% CI, 0.28-0.95). Nongenetic independent correlates were acuteness of PCI (adjusted OR, 3.05; 95% CI, 1.54-6.07), complex lesions (American College of Cardiology/American Heart Association type C) (adjusted OR, 2.33; 95% CI, 1.40-3.89), left ventricular function less than 40% (adjusted OR, 2.25; 95% CI, 1.09-4.70), diabetes mellitus (adjusted OR, 1.82; 95% CI, 1.02-3.24), use of proton pump inhibitors (adjusted OR, 2.19; 95% CI, 1.29-3.75), and higher clopidogrel loading doses (adjusted OR, 0.73; 95% CI, 0.57-0.93). The discriminative accuracy of the clinical-only model was similar to that of a genetic-only model (area under the curve, 0.73 [95% CI, 0.67-0.78] vs 0.68 [95% CI, 0.62-0.74], respectively; P=.34). A combined clinical and genetic model led to a statistically significant increase in the discriminatory power of the model compared with the clinical-only model (area under the curve, 0.78 [95% CI, 0.73-0.83] vs 0.73 [95% CI, 0.67-0.78]; P=.004). Conclusions This case-control study identified 3 genes (CYP2C19, ABCB1, and ITGB3) and 2 clopidogrel-related factors (loading dose and proton pump inhibitors) that were independently associated with early stent thrombosis. Future studies are needed to validate the prognostic accuracy of these risk factors in prospective cohorts. JAMA. 2011;306(16):1765-1774

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available